The FDA cleared PrecivityAD2, a blood test intended to help evaluate Alzheimer’s disease by detecting amyloid pathology. Developed and validated through technology pioneered at Washington University School of Medicine in St. Louis, the assay is now cleared for marketing as an aid in clinical assessment. For diagnostics developers, the clearance represents continued momentum for blood-based biomarkers that aim to standardize patient workups and streamline the path to further confirmatory testing. It also adds another commercially available tool to support decision-making in clinical settings where CSF or imaging access can be limited.